welcome to DuchenneXchange- a positively charged Duchenne muscular dystrophy community.
- join today!
Peak Cough Flow and Cough Clearance in Patients With Muscular Dystrophy
study id #: NCT02034305
condition: Duchenne Muscular Dystrophy
This study is to determine whether physiologic measures (peak cough flow, measures of respiratory muscle strength including MIP, MEP, SNIP, and spirometry) can predict spontaneous cough clearance (as measured by a nuclear medicine study) in children with neuromuscular disease. It will also determine whether airway clearance is augmented by high frequency chest wall oscillation.
mechanism of action: No pharmaceutical intervention
last updated: February 25, 2020
start date: January 2014
estimated completion: January 2021
phase of development: N/A
size / enrollment: 15
- Spontaneous cough clearance [ Time Frame: Assessed at multiple time points over 30 minutes ]
• Eligible Sexes: male
• Duchenne Muscular Dystrophy OR Becker Muscular Dystrophy
• Need for mechanical ventilation during the day
• Recent (within 2 weeks) lower respiratory tract infection
Safety and Dose Finding Study of NS-065/NCNP-01 in Boys With Duchenne Muscular Dystrophy (DMD)The main objective of this study is to e...
Trial of Pamrevlumab (FG-3019), in Non-Ambulatory Subjects With Duchenne Muscular Dystrophy (DMD)This is a Phase 2, open-label, single ar...
Historically Controlled Trial of Corticosteroids in Young Boys With Duchenne Muscular DystrophyWhile it has been known for many years t...
Duchenne Pulmonary Awareness: Assisted coughhttps://www.youtube.com/watch?v=qgTlNwXy...
A Study to Evaluate the Safety and Tolerability of PF-06939926 Gene Therapy in Duchenne Muscular DystrophyThis is a first-in-human/first-in-patien...
An Extension Study to Assess Vamorolone in Boys With Duchenne Muscular Dystrophy (DMD)The main purposes of this study are to s...
PTC Therapeutics Celebrates the Fifth Anniversary of STRIVE Grant Awards by Announcing 2019 Award WinnersSOUTH PLAINFIELD, N.J., Sept. 6, 2019 ...
Catabasis Pharmaceuticals Initiates Phase 3 PolarisDMD Clinical Trial For Edasalonexent In Duchenne Muscular Dystrop...Catabasis Pharmaceuticals, Inc., a clini...
Cardiac and Skeletal Muscle Effects in the Randomized HOPE-Duchenne TrialObjective: To assess the feasibility, s...
Sarepta Therapeutics to Provide Update on Duchenne Muscular Dystrophy Gene Therapy ProgramSarepta Therapeutics, Inc., the leader i...